Treatment for High- and Low-Risk HER2+ Breast Cancer

FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer ESMO 2024Подробнее

Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...Подробнее

HR+, HER2 , High Risk EBC A Practical Roadmap for CDK4 6 Inhibition in the Adjuvant SettingПодробнее

Current and emerging treatments for living well with early breast cancer- Dr Andy RedfernПодробнее

Systemic therapy in operable HER2 positive breast cancerПодробнее

Do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)Подробнее

HER2DX risk-score in early-stage HER2-positive breast cancerПодробнее

Personalising treatment in ER+/Her2 negative Early Breast CancerПодробнее

Focusing Decision-Making & Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCПодробнее

HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Ma...Подробнее

Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?Подробнее

Patients with High Risk Features | 2023 Best of Breast ConferenceПодробнее

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

Who gets Breast Cancer Recurrences? - with Dr TashaПодробнее

NYU Langone's Perlmutter Cancer Center Experts Discuss Advances in Breast Cancer 2022Подробнее

Recent Trends in Radiation Therapy for Breast Cancer 12/7/22Подробнее

Updates in Systemic Therapy for Breast Cancer 2/8/23Подробнее

HR+ Invasive Lobular Carcinoma Management - OncBrothers (Rohit & Rahul Gosain) w/ Dr. Jason MouabbiПодробнее

Adjuvant Therapy | 2023 Best of Breast ConferenceПодробнее

Lightning Updates | 2023 Best of Breast ConferenceПодробнее